05:12:14 EDT Mon 15 Aug 2022
Enter Symbol
or Name

Login ID:
Avicanna Inc
Symbol AVCN
Shares Issued 45,858,596
Close 2022-01-07 C$ 0.67
Recent Sedar Documents

Avicanna appoints Kim as chief legal officer

2022-01-10 10:27 ET - News Release

Mr. Aras Azadian reports


Avicanna USA Inc., together with Avicanna Inc., has appointed Stephen Kim as Avicanna's chief legal officer and general counsel.

Mr. Kim comes with over 20 years of legal experience with highly regulated and innovative industries. He has significant pharmaceutical industry experience and is very familiar with the complex overlay of corporate, commercial, intellectual property, governance, compliance and regulatory considerations associated with development, approval and launch of multiple pharmaceutical products, which he has executed in the United States, Canada and globally.

Prior to joining Avicanna, Mr. Kim held various roles of progressive responsibility at global biotechnology and pharmaceutical companies including Bayer Inc., Celgene Corp. and Indivior Inc., and also held roles as an associate with leading U.S. and international law firms in New York and Toronto. Mr. Kim graduated with a U.S. law degree from University of Detroit Mercy (JD) and a Canadian law degree from the University of Windsor (LLB).

"I am delighted to be joining Avicanna at such an exciting time and looking forward to partnering and working with the dynamic and visionary management team and with the accomplished and experienced members of the board of directors," Stephen Kim commented. "With my background and experience in domestic and cross-border transactions, as well as pharmaceutical product development, approval and launch, I am particularly excited about the company's work in the areas of evidence-based and pharmaceutical products and global business."

"We are thrilled to bring someone of Mr. Stephen Kim's calibre onboard as we evolve into the next phase of commercialization and development of our pharmaceutical pipeline. Stephen's experience and record coupled with his alignment of vision with the management team is precisely what the company needs to achieve its growth potential," Aras Azadian, chief executive officer, commented.

Mr. Kim will join the company at his role as the chief legal officer on Jan. 17, 2022, where he will oversee all legal and regulatory affairs at a global level.

About Avicanna Inc.

Avicanna is a Canadian commercial-stage biopharmaceutical company established in cannabinoid research, development and evidence-based products for the global consumer, as well as medical and pharmaceutical market segments. In leading global cannabinoid advancements, Avicanna conducts most of its research in Canada at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, located in the MaRS discovery district. The company actively collaborates with leading Canadian academic and medical institutions. Avicanna has established an industry-leading scientific platform, including advanced R&D and clinical development, which has led to the commercialization of over 20 products across four main market segments.

We seek Safe Harbor.

© 2022 Canjex Publishing Ltd. All rights reserved.